GAMMA Investing LLC increased its stake in shares of Pacira BioSciences, Inc. (NASDAQ:PCRX - Free Report) by 5,187.8% during the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 91,796 shares of the company's stock after buying an additional 90,060 shares during the quarter. GAMMA Investing LLC owned about 0.20% of Pacira BioSciences worth $2,281,000 at the end of the most recent quarter.
Other hedge funds and other institutional investors have also recently made changes to their positions in the company. Renaissance Technologies LLC lifted its position in Pacira BioSciences by 0.7% in the fourth quarter. Renaissance Technologies LLC now owns 1,992,601 shares of the company's stock valued at $37,541,000 after purchasing an additional 13,604 shares during the period. Geode Capital Management LLC raised its position in shares of Pacira BioSciences by 0.5% during the 4th quarter. Geode Capital Management LLC now owns 1,091,970 shares of the company's stock worth $20,578,000 after purchasing an additional 5,071 shares during the last quarter. Point72 Asset Management L.P. acquired a new position in shares of Pacira BioSciences during the 4th quarter worth approximately $20,266,000. Nuveen Asset Management LLC raised its position in shares of Pacira BioSciences by 109.9% during the 4th quarter. Nuveen Asset Management LLC now owns 625,917 shares of the company's stock worth $11,792,000 after purchasing an additional 327,754 shares during the last quarter. Finally, Northern Trust Corp raised its position in shares of Pacira BioSciences by 30.8% during the 4th quarter. Northern Trust Corp now owns 616,891 shares of the company's stock worth $11,622,000 after purchasing an additional 145,205 shares during the last quarter. Hedge funds and other institutional investors own 99.73% of the company's stock.
Pacira BioSciences Trading Down 0.9%
Shares of NASDAQ PCRX opened at $24.24 on Friday. Pacira BioSciences, Inc. has a 1-year low of $11.16 and a 1-year high of $29.61. The company has a 50-day moving average of $25.56 and a two-hundred day moving average of $23.58. The company has a current ratio of 2.25, a quick ratio of 1.89 and a debt-to-equity ratio of 0.51. The company has a market cap of $1.12 billion, a PE ratio of -11.94 and a beta of 0.52.
Insider Activity at Pacira BioSciences
In other Pacira BioSciences news, SVP Lauren Riker sold 5,578 shares of the company's stock in a transaction on Wednesday, June 4th. The shares were sold at an average price of $26.21, for a total transaction of $146,199.38. Following the sale, the senior vice president now directly owns 59,564 shares of the company's stock, valued at approximately $1,561,172.44. This represents a 8.56% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Corporate insiders own 6.40% of the company's stock.
Analyst Upgrades and Downgrades
Several brokerages have weighed in on PCRX. Barclays boosted their price target on Pacira BioSciences from $17.00 to $24.00 and gave the company an "overweight" rating in a report on Friday, February 28th. Wall Street Zen raised shares of Pacira BioSciences from a "hold" rating to a "buy" rating in a research report on Friday, June 6th. Needham & Company LLC cut their target price on shares of Pacira BioSciences from $32.00 to $30.00 and set a "buy" rating on the stock in a research note on Friday, May 9th. Finally, HC Wainwright upped their target price on shares of Pacira BioSciences from $48.00 to $65.00 and gave the stock a "buy" rating in a research report on Tuesday, April 8th. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating and five have given a buy rating to the stock. According to MarketBeat, the company presently has an average rating of "Hold" and an average target price of $26.44.
Check Out Our Latest Stock Report on PCRX
Pacira BioSciences Company Profile
(
Free Report)
Pacira Biosciences, Inc is a holding company, which engages in the provision of non-opioid pain management and regenerative health solutions to improve patients' journeys along the neural pain pathway. Its products include EXPAREL, iovera, and DepoFoam. The company was founded in December 2006 and is headquartered in Tampa, FL.
See Also
Want to see what other hedge funds are holding PCRX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pacira BioSciences, Inc. (NASDAQ:PCRX - Free Report).
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Pacira BioSciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Pacira BioSciences wasn't on the list.
While Pacira BioSciences currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
